Use of Biologics During Pregnancy Among Patients With Autoimmune Conditions
In this cohort study, a decline in the use of biologics for autoimmune disease was observed during the pregnancy period that rebounded only partially thereafter. Notable variations in use across autoimmune conditions suggest that indication-specific risk-benefit assessments of biologic use are needed.
Authors
- Yanning Wang (ORCID: https://orcid.org/0000-0002-4263-3944)
- Celeste L. Y. Ewig (ORCID: https://orcid.org/0000-0001-7372-3697)
- Nicole E. Smolinski (ORCID: https://orcid.org/0000-0002-0866-4579)
- Almut G. Winterstein (ORCID: https://orcid.org/0000-0002-6518-5961)
- Sonja A. Rasmussen (ORCID: https://orcid.org/0000-0002-0574-4928)
- Thuy Nhu Thai (ORCID: https://orcid.org/0000-0003-4544-1160)
Institutions
- Center for Drug Evaluation and Research (US)
- Harvard University (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- University of Florida (US)
- Harvard Pilgrim Health Care (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.10504
- Citations
- 7
- Primary Topic
- Pregnancy and Medication Impact
- Type
- article
- Field-Weighted Citation Impact
- 13.15
Funders
- Novo Nordisk
- Ipsen